HHV-8 vGPCR Signaling in Virus Biology
病毒生物学中的 HHV-8 vGPCR 信号转导
基本信息
- 批准号:7228721
- 负责人:
- 金额:$ 16.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-01-01 至 2008-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntiviral TherapyArrestinArrestinsB lymphoid malignancyBindingBiologyCell LineCell ProliferationClassCouplingDataDevelopmentDiseaseDissociationEatingEndothelial CellsEngineeringFeedbackFutureG Protein-Coupled Receptor SignalingG protein coupled receptor kinaseG-Protein-Coupled ReceptorsGenetic RecombinationGenomeGoalsHerpesviridaeHuman Herpesvirus 8In VitroKnock-outLaboratoriesLigandsLyticLytic PhaseMapsMediatingMediator of activation proteinMethodologyMolecularMusMutagenesisNeoplasmsOpen Reading FramesPathway interactionsPreparationProteinsReagentReceptor InhibitionRegulationRoleRole playing therapySerineSignal PathwaySignal TransductionSimplexvirusStructureSystemTailTechnologyThreonineTimeViralViral PathogenesisViral PhysiologyVirusVirus ReceptorsVirus Replicationangiogenesisarrestin3in vivoin vivo Modelinhibitor/antagonistlytic replicationmembermutantnovelprotein activationreceptorrecombinant virusresearch studytumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Human herpesvirus-8 (HHV-8) is a gamma-2 herpesvirus and, like many other members of the subfamily, is associated with neoplasia, including B cell malignancies and endothelial cell angioproliferative diseases. One of the HHV-8 proteins implicated in viral pathogenesis is the viral G protein-coupled receptor (vGPCR) encoded by open reading frame (ORF) 74. The receptor effects cellular proliferation and transformation in vitro and tumorigenesis and angiogenesis in vivo. GPCRs in other herpesviruses, including murine gamma- herpesvirus-68 (MHV-68), have been demonstrated to play roles in virus lytic replication, both in culture and in vivo. Understanding the mechanisms and regulation of HHV-8 vGPCR signaling is therefore relevant to attempts to control virus replication and associated disease. Previous structure-function studies of vGPCR in this laboratory identified receptor residues involved in Ga coupling and selectivity, and enabled dissociation of Ga subclass-activated pathways. The aims of this proposal are (1) to extend our previous structure-function studies of HHV-8 vGPCR to characterize the structural requirements for GRK-mediated negative regulation of vGPCR signaling, and (2) to utilize engineered functionally altered vGPCR proteins to investigate the roles of particular signaling pathways and vGPCR-regulatory mechanisms in virus replication. These studies will, for the first time, address the function of vGPCR in virus lytic replication, and provide enabling data, technology and reagents for future studies of the role of vGPCR-activated pathways and control mechanisms in disease development in in vitro and in vivo models of KS.
描述(申请人提供):人类疱疹病毒-8(HHV-8)是一种伽马-2疱疹病毒,与亚家族的许多其他成员一样,与肿瘤有关,包括B细胞恶性肿瘤和内皮细胞血管增生性疾病。HHV-8病毒致病蛋白之一是由开放阅读框架(ORF)74编码的病毒G蛋白偶联受体(VGPCR)。该受体在体外影响细胞的增殖和转化,在体内影响肿瘤的形成和血管生成。其他疱疹病毒中的GPCRs,包括小鼠伽玛-疱疹病毒-68(MHV-68),已被证明在病毒裂解复制中发挥作用,无论是在培养中还是在体内。因此,了解HHV-8vGPCR信号的机制和调节对于控制病毒复制和相关疾病的尝试是相关的。本实验室以前对vGPCR的结构和功能的研究发现,受体残基参与了GA偶联和选择性,并使GA亚类激活的通路能够解离。这一建议的目的是(1)扩展我们先前对HHV-8vGPCR的结构-功能研究,以表征GRK介导的vGPCR信号负调控的结构要求,以及(2)利用功能改变的工程vGPCR蛋白来研究特定的信号通路和vGPCR调控机制在病毒复制中的作用。这些研究将首次阐明vGPCR在病毒裂解复制中的作用,并为进一步研究vGPCR激活的途径和控制机制在KS体外和体内模型中的疾病发展提供可能的数据、技术和试剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Nicholas其他文献
John Nicholas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Nicholas', 18)}}的其他基金
HHV-8 vIRF interactions in the context of infection
HHV-8 vIRF 在感染情况下的相互作用
- 批准号:
8994365 - 财政年份:2015
- 资助金额:
$ 16.38万 - 项目类别:
HHV-8 vIRF interactions in the context of infection
HHV-8 vIRF 在感染情况下的相互作用
- 批准号:
9085244 - 财政年份:2015
- 资助金额:
$ 16.38万 - 项目类别:
Inhibitory targeting of HHV-8 vIL-6-related interactions.
HHV-8 vIL-6 相关相互作用的抑制性靶向。
- 批准号:
8595304 - 财政年份:2013
- 资助金额:
$ 16.38万 - 项目类别:
Inhibitory targeting of HHV-8 vIL-6-related interactions.
HHV-8 vIL-6 相关相互作用的抑制性靶向。
- 批准号:
8467210 - 财政年份:2013
- 资助金额:
$ 16.38万 - 项目类别:
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 16.38万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 16.38万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 16.38万 - 项目类别:
Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10481430 - 财政年份:2022
- 资助金额:
$ 16.38万 - 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10683329 - 财政年份:2022
- 资助金额:
$ 16.38万 - 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
- 批准号:
nhmrc : 1196520 - 财政年份:2021
- 资助金额:
$ 16.38万 - 项目类别:
Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10260234 - 财政年份:2021
- 资助金额:
$ 16.38万 - 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10548114 - 财政年份:2021
- 资助金额:
$ 16.38万 - 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
- 批准号:
10400318 - 财政年份:2020
- 资助金额:
$ 16.38万 - 项目类别:
Development of novel antiviral therapy targeting hepatitis B virus host restriction factor
针对乙型肝炎病毒宿主限制因子的新型抗病毒疗法的开发
- 批准号:
20K08371 - 财政年份:2020
- 资助金额:
$ 16.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)